Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. - Wikidata - awgldk - TriplyDB

Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

http://www.wikidata.org/entity/Q44691624

about

The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma Postoperative chemotherapy or radiotherapy for esophageal cancer Postoperative radiation in esophageal squamous cell carcinoma and target volume delineation Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review The role of induction therapy Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus Current Status and Future Prospects for Esophageal Cancer Treatment Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer.Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases.Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study.Current management of esophageal cancer Neoadjuvant treatment of esophageal cancer.Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma.Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy.Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.Perioperative therapy for esophageal cancer.Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies.Multimodality management of esophageal cancer.Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.The prognostic value of global DNA hypomethylation in cancer: a meta-analysis Clinical study on postoperative recurrence in patients with pN1 esophageal squamous cell carcinoma A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP.Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma Cytomegalovirus-associated ulceration of gastric conduit after chemoradiotherapy following esophagectomy for cancer A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma.Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.Better survival in patients with esophageal cancer after surgical treatment in university hospitals: a plea for performance by surgical oncologists Aggressive surgical resection does not improve survival in operable esophageal squamous cell carcinoma with N2-3 status.Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma The Impact of Postoperative Complications on Survivals After Esophagectomy for Esophageal Cancer.Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma.

P2860

Q21245478-5DCE5C0E-880E-41EB-941D-B9DD3BDA4696 Q24202240-530DEB3A-6380-4CF1-9386-AC0BCC92D6DB Q26741018-D591D60B-FFAD-4E3E-8835-940FB846999C Q26777898-67F9C3E2-6744-4F14-8C08-9479A75E6E22 Q26830698-41B459BF-2F6E-4321-9032-475D28E4A3B6 Q28259620-345A1CD8-7997-49B7-BA73-0863DD65451E Q28391760-9A90CFC0-3274-41A6-AF23-996777B7F20C Q30240008-D4292F29-8360-449C-BEB0-E2693CFB7462 Q30244382-01C0EE64-C74C-42C6-A9D9-E655B38302B5 Q30975636-E11B6C4F-CC02-4258-8923-51CDB77A8685 Q33628057-5B45FAA4-9FF2-462F-A71A-CF46B0BC9F0C Q33649971-57816031-E9C4-4D53-A5BB-314278D514A3 Q33653046-24BE696F-7D69-4F54-A97E-DBD6C20E8BF1 Q33658207-AE44B31F-6711-4C5C-A19B-1151C57F082E Q34063710-0B60D59B-E530-41ED-BA50-ED2E537ED97F Q34098746-D05AFF1E-9289-40F3-A0F5-84EFD7B90A5D Q34298027-5B501F74-A2A8-4899-867D-82673F5643BA Q34320528-9DC676FA-B280-4760-8A17-F4150B9F199A Q34441327-24F82FFA-AF7D-4DDC-AF1D-DC044AB16737 Q34479911-444A8780-0A6B-4737-820D-E7B1D2676D90 Q34522972-E0D3FFAF-0C7F-4290-91DB-BF26EE7A3C78 Q34627891-792510F1-29A1-4F15-85E6-9A03E5A8CBE7 Q34663544-108E6CB7-A23D-44CC-8D73-6FF854996A8B Q34689864-5472B8A9-29AC-4FA9-92B4-DA742BBE3E10 Q34981111-80218E6B-3974-4BB1-AE04-7B2D199DCE1A Q35028999-1C882580-44B0-414A-A542-5B21241C6788 Q35237505-34E95857-9FA5-45C7-ACF0-73A74932D87D Q35663621-6060778F-0E7F-44C1-BF1E-63DFD59BA653 Q35687667-C16F4596-D925-4F0D-9FFB-C7A7AFCA2986 Q35707383-23DE6086-1DA9-47C1-BE9C-FB9B0A8CF8FF Q35812694-C830629E-B09B-45AC-ACC9-A004B4055FA7 Q35820777-3871F7CD-F6B0-4453-9DA7-73516716D801 Q35835123-10B9BFAB-80BC-4050-BC79-F2EBC997CA0E Q35880879-4E3630EF-A7ED-4BA8-BD15-AEECF274F987 Q35891420-A12ADE5F-286E-4CF1-B774-1FA524264F79 Q36104323-B49930FD-9F74-429D-9138-15A13B039853 Q36194108-6A1620A2-8359-487E-BEAE-E1BE8BF88370 Q36392390-75AD4CBE-6101-4E35-9082-C0B45E013EC9 Q36413366-8B0B42BD-31D1-4D0C-ADB6-9A4B1F562986 Q36546082-BB3A998E-2ED3-4E9E-9C3E-7A014436357F

P2860

Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

http://www.wikidata.org/entity/Q44691624

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Surgery plus chemotherapy comp ...... ncology Group Study--JCOG9204.

@en

Surgery plus chemotherapy comp ...... ncology Group Study--JCOG9204.

@nl

type

label

Surgery plus chemotherapy comp ...... ncology Group Study--JCOG9204.

@en

Surgery plus chemotherapy comp ...... ncology Group Study--JCOG9204.

@nl

prefLabel

Surgery plus chemotherapy comp ...... ncology Group Study--JCOG9204.

@en

Surgery plus chemotherapy comp ...... ncology Group Study--JCOG9204.

@nl

P1433

Q44691624-9C86D77D-C1E2-407D-B9B3-7D4C4E649368

P1476

Q44691624-EF5124F6-5303-409A-B0DA-EAF9D083DFFA

P2093

Q44691624-0726995F-687C-41FD-943D-8C18245C56D4

Q44691624-1242EFC9-A112-4E5E-AF51-240A5A9E9058

Q44691624-3FE6E940-9DC7-45A1-9650-EF8CB0C388A2

Q44691624-56B47231-7AD7-4277-B613-784992D98EA2

Q44691624-57F8E86F-016D-4FC2-894C-C970B462A364

Q44691624-6AAE638C-D9F2-45B4-8035-BD232DED430A

Q44691624-7ACE8CE9-E820-4BE0-8286-98B10CB96107

Q44691624-82514032-3AB4-437D-9AF6-00D47D29D63D

Q44691624-98F7AA8E-6A43-48FD-B54A-87A2B23DAAFE

Q44691624-A273A9A8-A652-4D1A-960E-4AA0937C5EDE

P304

Q44691624-9C0369FA-177E-4A5C-AF8A-5B0208BACAC6

P31

Q44691624-1E8C427F-225C-42EB-8321-75123402A770

P356

Q44691624-75A6E96C-34D8-4A60-998E-5AE9E6BED3F7

P407

Q44691624-C72EB891-C2B2-4E61-A960-B59109CC42E6

P433

Q44691624-B962E7AA-F045-4511-8A50-2D33C23BA2C1

P478

Q44691624-AEC80B85-1278-4F06-874E-D50F6B9A6DA3

P577

Q44691624-D6BE7B4A-BFC6-43EC-9CD5-5AFDB47B051B

P698

Q44691624-D2F537BB-38F6-49B5-A523-AD8189A690B7

P921

Q44691624-F634C7AE-0F08-4A79-89A1-77A01C4C70E3

P356

JCO.2003.12.095

P1433

Journal of Clinical Oncology

P1476

Surgery plus chemotherapy comp ...... ncology Group Study--JCOG9204.

@en

P2093

Haruhiko Fukuda

http://www.w3.org/2001/XMLSchema#string

Hideaki Yamana

http://www.w3.org/2001/XMLSchema#string

Hiroko Ide

http://www.w3.org/2001/XMLSchema#string

Hiroshi Watanabe

http://www.w3.org/2001/XMLSchema#string

Hiroyasu Makuuchi

http://www.w3.org/2001/XMLSchema#string

Japan Clinical Oncology Group

http://www.w3.org/2001/XMLSchema#string

Kagami Nagai

http://www.w3.org/2001/XMLSchema#string

Kaichi Isono

http://www.w3.org/2001/XMLSchema#string

Kaoru Ishida

http://www.w3.org/2001/XMLSchema#string

Masayuki Shinoda

http://www.w3.org/2001/XMLSchema#string

P304

4592-4596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.12.095

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14673047

http://www.w3.org/2001/XMLSchema#string

P921